Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Expert on PD-L1/CTLA-4 Blockade and Future of Immunotherapy in Lung Cancer

March 17th 2016

Scott J. Antonia, MD, discusses how the combination of the PD-L1 inhibitor durvalumab and the CTLA-4 inhibitor tremelimumab, showed antitumor activity in patients with locally advanced or metastatic non–small cell lung cancer, irrespective of PD-L1 status.

Dr. Chandra Belani on Atezolizumab in NSCLC

March 16th 2016

Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses atezolizumab in non-small cell lung cancer (NSCLC).

FDA Approves Crizotinib for ROS1-Positive NSCLC

March 11th 2016

The FDA has approved crizotinib as a treatment for patients with ROS1-positive metastatic non–small cell lung cancer.

Nivolumab, Pembrolizumab Compete for Top Choice in NSCLC Treatment

March 8th 2016

Benjamin Levy, MD, discusses how nivolumab and pembrolizumab have impacted the treatment landscape of NSCLC, how to choose between the two for patients, and what biomarkers are in development for PD-1/PD-L1 agents.

FDA Accepts Application to Expand Pembrolizumab NSCLC Indication

March 7th 2016

The FDA has accepted a supplemental new drug application for pembrolizumab as a treatment for patients with advanced non–small cell lung cancer with PD-L1 expression on ≥1% of tumors cells.

Dr. Belani on Impact of Nivolumab's Approval in NSCLC

March 4th 2016

Chandra P. Belani, MD, Miriam Beckner Distinguished Professor of Medicine, Penn State Milton S. Hershey Medical Center, deputy director, Penn State Hershey Cancer Institute, discusses how the FDA approval of nivolumab (Opdivo) has impacted the treatment paradigm of non–small cell lung cancer (NSCLC).

Optimal Sequencing in Squamous Non-Small Cell Lung Cancer

March 3rd 2016

TKIs in Squamous NSCLC: LUX-Lung-8

March 3rd 2016

Ipilimumab in Squamous Non-Small Cell Lung Cancer

March 3rd 2016

Safety of PD-1 Inhibitors in Squamous NSCLC

March 3rd 2016

PD-L1 as a Biomarker in Squamous Non-Small Cell Lung Cancer

March 3rd 2016

Immune Checkpoint Inhibitors in Squamous Non-Small Cell Lung Cancer

March 3rd 2016

Clinical Trial Results of Ramucirumab in Squamous NSCLC

March 3rd 2016

Monoclonal Antibodies in Squamous Cell Lung Cancer

March 3rd 2016

Treatment Options for Relapsed Squamous NSCLC

March 3rd 2016

Maintenance Therapy in Squamous NSCLC

March 3rd 2016

Nab-Paclitaxel plus Carboplatin in Squamous NSCLC

March 3rd 2016

Optimal Chemotherapy for Squamous NSCLC

March 3rd 2016

Mutation Testing and Lung-MAP Clinical Trial

March 3rd 2016

Mutational Landscape of Squamous NSCLC

March 3rd 2016

NEXT PAGE
PREVIOUS PAGE